{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:41:35Z","timestamp":1790800895746,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Since the beginning of the COVID-19 pandemic and development of new vaccines, the issue of post-vaccination exacerbation or manifestation of demyelinating central nervous system (CNS) disorders has gained increasing attention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present a case of a 68-year-old woman previously diagnosed with multiple sclerosis (MS) since the 1980s who suffered a rapidly progressive severe sensorimotor paraparesis with loss of bladder and bowel control due to an acute longitudinal extensive transverse myelitis (LETM) after immunization with the mRNA Pfizer\u2013BioNTech COVID-19 vaccine. Detection of Aquaporin-4-antibodies (AQP4) in both serum and CSF led to diagnosis of AQP4-antibody positive neuromyelitis optica spectrum disorder (NMOSD). Treatment with intravenous corticosteroids and plasmapheresis led to a slight improvement of the patient\u2019s symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pathogenic mechanisms of post-vaccination occurrence of NMOSD are still unknown. However, cases like this should make aware of rare neurological disorders manifesting after vaccination and potentially contribute to improvement of management of vaccinating patients with inflammatory CNS disorders in the future. So far two cases of AQP4-antibody positive NMOSD have been reported in association with viral vector COVID-19 vaccines. To our knowledge, we report the first case of AQP4-antibody positive NMOSD after immunization with an mRNA COVID-19-vaccine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02698-y","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:05:46Z","timestamp":1652850346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-6883","authenticated-orcid":false,"given":"Lisa","family":"Lohmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"M\u00f6ddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2698_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","volume":"13","author":"D Karussis","year":"2014","unstructured":"Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13:215\u201324. https:\/\/doi.org\/10.1016\/j.autrev.2013.10.003.","journal-title":"Autoimmun Rev"},{"key":"2698_CR2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","volume":"71","author":"A Langer-Gould","year":"2014","unstructured":"Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014;71:1506\u201313. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2633.","journal-title":"JAMA Neurol"},{"key":"2698_CR3","doi-asserted-by":"publisher","unstructured":"Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2021. https:\/\/doi.org\/10.1007\/s10072-021-05662-9.","DOI":"10.1007\/s10072-021-05662-9"},{"key":"2698_CR4","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s10072-021-05427-4","volume":"42","author":"S Chen","year":"2021","unstructured":"Chen S, Fan X-R, He S, Zhang J-W, Li S-J. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol Sci. 2021;42:3537\u20139. https:\/\/doi.org\/10.1007\/s10072-021-05427-4.","journal-title":"Neurol Sci"},{"key":"2698_CR5","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1016\/j.radcr.2021.09.033","volume":"16","author":"N Badrawi","year":"2021","unstructured":"Badrawi N, Kumar N, Albastaki U. Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings. Radiol Case Rep. 2021;16:3864\u20137. https:\/\/doi.org\/10.1016\/j.radcr.2021.09.033.","journal-title":"Radiol Case Rep"},{"key":"2698_CR6","doi-asserted-by":"publisher","first-page":"e17961","DOI":"10.7759\/cureus.17961","volume":"13","author":"P Fujikawa","year":"2021","unstructured":"Fujikawa P, Shah FA, Braford M, Patel K, Madey J. Neuromyelitis optica in a healthy female after severe acute respiratory syndrome coronavirus 2 mRNA-1273 vaccine. Cureus. 2021;13:e17961. https:\/\/doi.org\/10.7759\/cureus.17961.","journal-title":"Cureus."},{"key":"2698_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389. https:\/\/doi.org\/10.1212\/WNL.0000000000001729.","journal-title":"Neurology."},{"key":"2698_CR8","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/1352458517703803","volume":"23","author":"J-i Kira","year":"2017","unstructured":"Kira J-i. Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? Mult Scler. 2017;23:1300\u20132. https:\/\/doi.org\/10.1177\/1352458517703803.","journal-title":"Mult Scler"},{"key":"2698_CR9","doi-asserted-by":"publisher","first-page":"103394","DOI":"10.1016\/j.msard.2021.103394","volume":"58","author":"H Cai","year":"2022","unstructured":"Cai H, Zhou R, Jiang F, Zeng Q, Yang H. Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy? Mult Scler Relat Disord. 2022;58:103394. https:\/\/doi.org\/10.1016\/j.msard.2021.103394.","journal-title":"Mult Scler Relat Disord."},{"key":"2698_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1212\/WNL.0b013e31825fdead","volume":"79","author":"T Menge","year":"2012","unstructured":"Menge T, Cree B, Saleh A, Waterboer T, Berthele A, Kalluri SR, et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 2012;79:285\u20137. https:\/\/doi.org\/10.1212\/WNL.0b013e31825fdead.","journal-title":"Neurology."},{"key":"2698_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.msard.2016.11.009","volume":"11","author":"F Sch\u00f6berl","year":"2017","unstructured":"Sch\u00f6berl F, Csanadi E, Eren O, Dieterich M, K\u00fcmpfel T. NMOSD triggered by yellow fever vaccination - An unusual clinical presentation with segmental painful erythema. Mult Scler Relat Disord. 2017;11:43\u20134. https:\/\/doi.org\/10.1016\/j.msard.2016.11.009.","journal-title":"Mult Scler Relat Disord"},{"key":"2698_CR12","doi-asserted-by":"publisher","unstructured":"Ismail II, Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J Neurol. 2021. https:\/\/doi.org\/10.1007\/s00415-021-10752-x.","DOI":"10.1007\/s00415-021-10752-x"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02698-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:05:49Z","timestamp":1652850349000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02698-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2698"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02698-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and all images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LL and FG declare that they have no competing interests. GM received industry-funded travel support from Desitin Arzneimittel, Eisai Pharma, and UCB Pharma, as well as speaking honoraria from UCB Pharma. JDL received speaker fees, research support, and served on advisory boards at the Swiss National Science Foundation, the Swiss Multiple Sclerosis Society, AbbVie, Alexion, ArgenX, Bayer AG, Biogen Inc., Sanofi Genzyme, Merck & Co., Novartis AG, F. Hoffmann-La Roche. HW received honoraria for acting as a member of scientific advisory boards for Biogen, Evgen, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Aventis as well as speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinn\u00fctzige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Genzyme, Teva, and WebMD Global. He is acting as a paid consultant for Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis, and the Swiss rheuma Society. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and Biogen, GlaxoSmithKline GmbH, Roche Pharma AG, and Sanofi-Genzyme. LK received compensation for serving on scientific advisory boards for Alexion, Genzyme, Janssen, Merck Serono, Novartis, and Roche. She received speaker honoraria and travel support from Bayer, Biogen, Genzyme, Grifols, Merck Serono, Novartis, Roche, Santhera, and Teva. She receives research support from the German Research Foundation, the IZKF M\u00fcnster, IMF M\u00fcnster, Biogen, Immunic AG, Novartis, and Merck Serono.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}